<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867656</url>
  </required_header>
  <id_info>
    <org_study_id>KS-4-Diabetes-19</org_study_id>
    <nct_id>NCT03867656</nct_id>
  </id_info>
  <brief_title>Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19</brief_title>
  <official_title>Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both GLP-2 and GIP reduce the bone resorption (measured as CTX) in healthy persons. In this
      study, we will investigate wether GLP-2 and GIP is reducing CTX in persons with type 2
      diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">June 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is a crossover study with the following interventions: GLP-2, GIP, and placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTX</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Bone resorption measured as collagen type 1 C-terminal telopeptide (CTX) in serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>P1NP</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Bone formation measured as procollagen type 1 N-terminal propeptide (P1NP) in serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>PTH measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>-10 min to 240 min.</time_frame>
    <description>Bone marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Glucose-dependent insulinotropic polypeptide measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-2</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Glucagon-like peptide 2 measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Glucagon measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Measured before blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>-10 minutes to 240 minutes</time_frame>
    <description>Measured before blood sampling</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon-like peptide 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose-dependent insulinotropic polypeptide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-2</intervention_name>
    <description>GLP-2 injection</description>
    <arm_group_label>GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP</intervention_name>
    <description>GIP injection</description>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age 25 to 70 years old.

          -  Type 2 diabetes.

          -  In Metformin or sulfonylureas

        Exclusion Criteria:

          -  Treatment with other antidiabetics

          -  Osteopososis or gastrointestinal disease

          -  Smoking

          -  Long term steroid treatment

          -  Weight change more than 3 kg within the last 3 months.

          -  Overweight or intestinal surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Rosenkilde, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsa Skov-Jeppesen, Cand.pharm.</last_name>
    <phone>26818619</phone>
    <email>kirsa@sund.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mette Rosenkilde</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sten Madsbad, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kirsa Skov-Jeppesen</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kirsa Skov-Jeppesen, Cand.pharm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Kirsa Skov-Jeppesen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Bone resorption</keyword>
  <keyword>Bone formation</keyword>
  <keyword>CTX</keyword>
  <keyword>P1NP</keyword>
  <keyword>GLP-2</keyword>
  <keyword>GIP</keyword>
  <keyword>Bone turnover</keyword>
  <keyword>Bone remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

